Flash Finance

Themis Medicare LimitedTHEMISMEDCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹106.53
MCap ₹989 Cr · P/E 33.1
Themis Medicare Limited — Stock analysis & AI research Themis Medicare Limited — Seasonality — best & worst months Themis Medicare Limited — Technical setup — score, trend, support & resistance Themis Medicare Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹87 Cr
Sales · Jun 2026
-10.9% YoY
₹-52 Cr
Operating Profit · Jun 2026
-420.2% YoY
-60.3%
OPM % · Jun 2026
-485.4% YoY
₹29 Cr
Net Profit · Jun 2026
+286.9% YoY
₹3.12
EPS · Jun 2026
+286.8% YoY

📝 Themis Medicare Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Themis Medicare Limited reported revenue of ₹87 crore for the quarter ended June 2026 (Q1 FY27), down 10.9% from ₹98 crore in the same quarter last year, and up 13.6% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹29 crore from a net loss of ₹15 crore a year earlier. Earnings per share (EPS) came in at ₹3.12.

Operating profit stood at ₹-52 crore — an operating margin (OPM) of -60.3%, compared with -10.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Themis Medicare Limited posted revenue of ₹342 crore, a decline of 7.8% over FY25, with a net loss of ₹14 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹332 crore with a net profit of ₹30 crore.

Valuation snapshot

At the current price of ₹106.53, THEMISMED has a market capitalisation of ₹989 crore and a trailing P/E of about 33.1.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 67.11%, foreign institutional investors (FIIs) 0.01%, domestic institutional investors (DIIs) 0.01%, public shareholders 32.87% of Themis Medicare Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹989 Cr
Current Price ?
₹106.5
P/E ?
33.06below ind
Industry P/E ?
37.20
P/B ?
3.29
P/S ?
2.98
P/FCF ?
-123.69
Enterprise Value ?
₹1,089 Cr
EV/EBITDA ?
-25.98
PEG ?
N/A
Earnings Yield ?
-4.8%
Dividend Yield ?
0.47%
Profitability & Returns
Sales (TTM) ?
₹332 Cr
OPM ?
-12.6%
Profit after tax (TTM) ?
₹30 Cr
EPS (TTM) ?
₹3.22
ROCE ?
0.0%
ROE ?
9.9%
ROA ?
6.0%
Growth
Sales — latest qtr ?
₹87 Cr
PAT — latest qtr ?
₹29 Cr
YoY qtr sales growth ?
-10.9%
YoY qtr profit growth ?
286.9%
Sales growth (3y) ?
-1%
Sales growth (5y) ?
8%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹100 Cr
Debt to Equity ?
0.33
Interest Coverage ?
-0.9
Current Ratio ?
N/A
Ownership
Promoter holding ?
67.11%
Change in promoter holding ?
-0.04%
Pledged percentage ?
N/A
Market
Return 3 months ?
-3.1%
Return 6 months ?
18.3%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 898097105837610610094729878907787 -10.9% +13.6%
Operating Profit 151022128829179-6-10-3104-52 -420.2% -1490.4%
Other Income 63121-0111213141 -15.5% -72.9%
Interest 232232123223333 +20.5% +10.3%
Depreciation 333331113333333 -0.4% -2.2%
Profit Before Tax 16817103628154-9-15-55243 +380.7% +1896.4%
Net Profit 1261372319103-8-15-55229 +286.9% +1358.7%
EPS 13.140.6613.640.770.220.342.031.080.33-0.84-1.67-0.580.500.213.12 +286.8% +1385.7%
OPM % 17.2% 13.1% 22.5% 11.8% 9.8% 11.2% 27.6% 17.1% 9.1% -8.1% -10.3% -4.0% 10.9% 4.9% -60.3% -485.4% -1330.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹371 Cr ₹342 Cr ₹332 Cr -7.8%
Operating Profit ₹49 Cr ₹0 Cr ₹-42 Cr -99.2%
OPM % 13.21% 0.12% -12.65% -99.1%
NPM % 6.44% -4.14% 9.03% -164.3%
Other Income ₹4 Cr ₹9 Cr ₹9 Cr +131.1%
Depreciation ₹7 Cr ₹10 Cr ₹10 Cr +44.5%
Interest ₹8 Cr ₹11 Cr ₹11 Cr +29.1%
EBIT ₹42 Cr ₹-10 Cr ₹-52 Cr -123.7%
PBT ₹38 Cr ₹-13 Cr ₹45 Cr -135.6%
Tax ₹11 Cr ₹1 Cr ₹14 Cr -94.3%
Net Profit ₹24 Cr ₹-14 Cr ₹30 Cr -159.3%
EPS ₹2.60 ₹-1.54 ₹3.25 -159.2%
Material Cost ₹130 Cr ₹95 Cr ₹128 Cr -27.3%
Employee Cost ₹91 Cr ₹72 Cr ₹70 Cr -20.3%
Extraordinary Items — ₹-2 Cr ₹99 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 9999 +0.0%
Reserves 273292311292 -6.1%
Borrowings 929683100 +20.5%
Other Liabilities 829310299 -2.9%
Total Liabilities 456490506500 -1.2%
Fixed Assets 162168172167 -2.9%
CWIP 3332 -33.3%
Investments 11111111 +0.0%
Other Assets 280308320320 +0.0%
Total Assets 456490506500 -1.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 162235-3 -108.6%
Cash from Investing Activity -24-16-12-3 +75.0%
Cash from Financing Activity 0-9-264 +115.4%
Net Cash Flow -8-3-3-2 +33.3%
Free Cash Flow -13421-8 -138.1%
CFO/OP 48%60%93%-356% -482.8%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 150170160190 +18.8%
Inventory Days 213188233229 -1.7%
Days Payable 123126142143 +0.7%
Cash Conversion Cycle 239233251275 +9.6%
Working Capital Days 111117123138 +12.2%
ROCE % 20%11%11%-0% -100.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 67.15%67.15%67.10%67.10%67.11% +0.0%
FIIs 0.09%0.06%0.05%0.11%0.01% -90.9%
DIIs 0.01%0.01%0.01%0.01%0.01% +0.0%
Public 32.75%32.77%32.84%32.78%32.87% +0.3%
No. of Shareholders 19,33522,49022,57621,81821,267 -2.5%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 THEMISMED Themis Medicare ₹128.43 1,193 29.5 332 40 -12.5% 12.2% -15.6% -96.2% -10.8% 275.8%
❓ Frequently asked questions
What was Themis Medicare Limited's revenue in Q1 FY27?
Themis Medicare Limited reported revenue of ₹87 crore for the quarter ended June 2026 (Q1 FY27), down 10.9% from ₹98 crore in the same quarter last year, and up 13.6% sequentially over the March 2026 quarter.
What was Themis Medicare Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹29 crore from a net loss of ₹15 crore a year earlier. Earnings per share (EPS) came in at ₹3.12.
What is THEMISMED's market capitalisation and P/E ratio?
At the current price of ₹106.53, THEMISMED has a market capitalisation of ₹989 crore and a trailing P/E of about 33.1.
Who owns Themis Medicare Limited? (shareholding pattern)
As of Jun 2026, promoters held 67.11%, foreign institutional investors (FIIs) 0.01%, domestic institutional investors (DIIs) 0.01%, public shareholders 32.87% of Themis Medicare Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI